University of North Carolina Chapel Hill School of Medicine, 321 S Columbia St, Chapel Hill, NC 27599, USA.
University of North Carolina Chapel Hill Department of Dermatology, 410 Market Street Suite 400A, Chapel Hill, NC 27516, USA.
Immunotherapy. 2024;16(16-17):1005-1013. doi: 10.1080/1750743X.2024.2401308. Epub 2024 Sep 19.
Hidradenitis suppurativa (HS) is a painful, inflammatory dermatosis involving recurrent abscesses, nodules and tunnels in intertriginous regions. Biologics and other immunomodulators have significantly expanded the treatment options available for HS. Bimekizumab is a monoclonal antibody targeting both interleukin-17A and interleukin-17F, key mediators of inflammation, that is already approved for psoriasis, psoriatic arthritis and axial spondylarthritis. It is currently pending FDA review for HS treatment but has already received marketing authorization for this indication in Europe. This review aims to explore drug-specific characteristics of bimekizumab including its mechanism of action, pharmacokinetics and pharmacodynamics and the current state of the literature regarding its use in HS such as safety, efficacy and dosing, while highlighting its implications in clinical practice. Recent Phase II and III trial data demonstrating positive efficacy and safety profiles in the treatment of HS will also be detailed.
化脓性汗腺炎（HS）是一种疼痛性炎症性皮肤病，涉及易摩擦部位反复发作的脓肿、结节和瘘道。生物制剂和其他免疫调节剂极大地扩展了 HS 的治疗选择。Bimekizumab 是一种针对白细胞介素-17A 和白细胞介素-17F 的单克隆抗体，这两种细胞因子是炎症的关键介质，已被批准用于治疗银屑病、银屑病关节炎和中轴型脊柱关节炎。它目前正在接受 FDA 对 HS 治疗的审查，但已在欧洲获得该适应症的上市许可。本综述旨在探讨 bimekizumab 的药物特异性特征，包括其作用机制、药代动力学和药效学，以及目前关于其在 HS 中的应用的文献，如安全性、疗效和剂量，同时强调其在临床实践中的意义。还将详细介绍最近的 II 期和 III 期试验数据，这些数据表明 bimekizumab 在治疗 HS 方面具有积极的疗效和安全性。
